Loading…
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-155M | $-138M | $-107M | -34.4% | - | 102.9% |
| 2024 | $0M | $-82M | $-68M | $-75M | -13.8% | - | 30.8% |
| 2023 | $0M | $-40M | $-52M | $-46M | 34.9% | - | 37.4% |
| 2022 | $0M | $-38M | $-38M | $-32M | 38.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 37.66 | 39.89 | 82.39 | 155.60 |
| Research And Development | 31.31 | 30.62 | 63.62 | 125.10 |
| Selling General And Administration | 6.34 | 9.27 | 18.77 | 30.51 |
| Total Expenses | 37.66 | 39.89 | 82.39 | 155.60 |
| Operating Income | -37.66 | -39.89 | -82.39 | -155.60 |
| Total Operating Income As Reported | -37.66 | -39.89 | -82.39 | -155.60 |
| EBITDA | -37.72 | -39.87 | -82.33 | -155.50 |
| Normalized EBITDA | -37.72 | -39.87 | -82.33 | -155.50 |
| EBIT | -37.73 | -39.89 | -82.39 | -155.60 |
| Interest Income | 0 | 1.31 | 14.58 | 17.87 |
| Interest Expense | 0.11 | 0 | - | - |
| Net Interest Income | -0.11 | 1.31 | 14.58 | 17.87 |
| Other Non Operating Income Expenses | -0.08 | -13.40 | - | - |
| Other Income Expense | -0.08 | -13.40 | - | - |
| Interest Income Non Operating | 0 | 1.31 | 14.58 | 17.87 |
| Interest Expense Non Operating | 0.11 | 0 | - | - |
| Net Non Operating Interest Income Expense | -0.11 | 1.31 | 14.58 | 17.87 |
| Pretax Income | -37.84 | -51.98 | -67.81 | -137.73 |
| Tax Provision | 0 | 0 | 0.19 | 0.22 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -37.84 | -51.98 | -68 | -137.95 |
| Net Income From Continuing And Discontinued Operation | -37.84 | -51.98 | -68 | -137.95 |
| Net Income From Continuing Operation Net Minority Interest | -37.84 | -51.98 | -68 | -137.95 |
| Net Income | -37.84 | -51.98 | -68 | -137.95 |
| Net Income Common Stockholders | -37.84 | -51.98 | -68 | -137.95 |
| Net Income Including Noncontrolling Interests | -37.84 | -51.98 | -68 | -137.95 |
| Normalized Income | -37.84 | -51.98 | -68 | -137.95 |
| Diluted NI Availto Com Stockholders | -37.84 | -51.98 | -68 | -137.95 |
| Basic Average Shares | 15.44 | 33.98 | 16.81 | 54.68 |
| Diluted Average Shares | 15.44 | 33.98 | 16.81 | 54.68 |
| Reconciled Depreciation | 0.01 | 0.02 | 0.06 | 0.10 |
| General And Administrative Expense | 6.34 | 9.27 | 18.77 | 30.51 |
| Other Gand A | 2.54 | 9.27 | 6.22 | 9.93 |
| Salaries And Wages | 3.80 | 5.82 | 12.54 | 20.58 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc.this co. | BCAX | $1.3B | -9.72 | 3.34 | -34.4% | -8.01 |
| Butterfly Network, Inc. | BFLY | $1.4B | - | 6.93 | -39.3% | - |
| UroGen Pharma Ltd. | URGN | $1.3B | -8.76 | -12.75 | 145.5% | -10.04 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B | -9.56 | 167.49 | -1752.2% | -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B |
| -21.66 |
| 7.99 |
| -36.9% |
| -50.52 |
| Tandem Diabetes Care, Inc. | TNDM | $1.3B | -6.51 | 8.59 | -131.9% | -9.55 |
| AdaptHealth Corp. | AHCO | $1.3B | -18.70 | 0.87 | -4.7% | 6.60 |
| BioLife Solutions, Inc. | BLFS | $1.3B | -288.04 | 3.56 | -1.2% | -109.81 |
| Teladoc Health, Inc. | TDOC | $1.3B | -6.59 | 0.95 | -14.5% | 9.83 |
| Peer Median | - | -9.56 | 5.24 | -25.7% | -10.04 | |